Reaffirms 2025 adjusted earnings guidance in the range of $4.00 to $4.20 per share, excluding merger-related costs, same as prior GAAP guidanceCompleted planned equity and debt financing activities fo ...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 ...

Harnessing the ocean's predictable power, the market is advancing beyond demonstration projects. Tidal energy, with its ...